A c-SNP, or coding SNP, is a single nucleotide polymorphism that occurs within the protein-coding region of a gene. While most SNPs in the human genome sit in non-coding stretches of DNA between genes, coding SNPs are located in the portions of genes that directly instruct the body to build proteins. That location makes them more likely to affect how a protein works, and in some cases, more likely to influence disease risk or drug response.
How a c-SNP Differs From Other SNPs
A single nucleotide polymorphism is a one-letter change in DNA. Your genome contains millions of them, and the vast majority are harmless background variation. Most SNPs fall in regions between genes, where they have little or no effect on the body’s day-to-day operations. A c-SNP is simply one that lands inside a gene’s coding sequence, the stretch of DNA that gets translated into a protein.
Because proteins carry out nearly every function in the body, a change in the instructions for building one can have real consequences. Not every c-SNP causes problems, though. There are two main categories:
- Synonymous (silent) c-SNPs change a DNA letter but still code for the same amino acid. The protein comes out identical, so the effect is usually negligible.
- Non-synonymous c-SNPs swap one amino acid for another in the finished protein. This can alter how the protein folds, how stable it is, or how it interacts with other molecules in the cell.
Non-synonymous variants are the ones that get the most attention in medical genetics, because they’re the most likely to change what a protein actually does.
How a Single Letter Change Alters a Protein
Proteins are long chains of amino acids that fold into precise three-dimensional shapes. That shape determines function. When a non-synonymous c-SNP swaps in a different amino acid, it can disrupt the folding pattern, weaken the protein’s structural stability, or change the surface where the protein docks with a partner molecule.
A well-documented example involves a mutation in a DNA-repair gene called RAD51L3, where a single amino acid substitution cut the protein’s ability to bind its partner protein in half. The substituted amino acid disrupted interactions between different sections of the protein, reshaping its fold just enough to impair function. This kind of cascade, one letter of DNA leading to a measurably weaker protein partnership, illustrates why c-SNPs attract so much research interest even though they represent a small fraction of total human genetic variation.
Why c-SNPs Are Relatively Rare
Only about 1.5% of the human genome codes for proteins, so the sheer odds of any given SNP landing in a coding region are low. But there’s a second force keeping c-SNPs uncommon: natural selection. Changes in coding regions that harm protein function tend to reduce an organism’s fitness, so they get weeded out over generations.
Research in plant genomes has quantified this pressure. At synonymous sites (where the protein doesn’t change), SNPs that disrupt the local RNA structure show about a 13.4% reduction in genetic diversity compared to SNPs that leave the structure intact, and they appear at lower frequencies in the population. Non-synonymous changes face even steeper selection. The pattern holds across species: the more a DNA change threatens protein function, the less likely it is to persist and spread.
How c-SNPs Are Named
Researchers use a standardized naming system maintained by the Human Genome Variation Society (HGVS). At the protein level, a c-SNP is written as the original amino acid, its position number, and the new amino acid. For example, p.Ser321Arg means that serine at position 321 has been replaced by arginine. The three-letter amino acid code is preferred over single-letter abbreviations for clarity.
You’ll also see c-SNPs referenced by an “rs” number (like rs1234567), which is a database identifier assigned by dbSNP, the largest public catalog of human genetic variants. The rs number is a universal label that links to all known information about that variant, while the HGVS notation tells you exactly what changed at the protein level.
c-SNPs in Drug Response
Some of the most practical applications of c-SNP research involve pharmacogenomics, the study of how genetic variation affects your response to medications. Coding variants in a handful of key gene families account for a large share of person-to-person differences in drug metabolism and side effects.
Drug-metabolizing enzymes are the best-known example. Genes like CYP2D6 and CYP2C19 encode liver enzymes that break down dozens of common medications, from antidepressants to pain relievers. A c-SNP in one of these genes can make the enzyme faster or slower than normal, meaning the same dose of a drug produces very different blood levels in different people.
Drug transporter genes (such as SLCO1B1 and ABCG2) control how medications move into and out of cells. Coding variants here can change how much of a drug reaches its target tissue. Drug target genes matter too. The blood thinner warfarin works by blocking a protein called VKORC1, which recycles vitamin K for blood clotting. Genetic variation that increases or decreases the amount of VKORC1 your body produces can shift the warfarin dose you need by a wide margin.
Immune-system genes in the HLA family carry c-SNPs that influence the risk of severe allergic reactions to certain drugs. Testing for these variants before prescribing is already standard practice for a few medications, and the list is growing as more coding variants are mapped to drug outcomes.
c-SNPs vs. Non-Coding SNPs in Disease Research
Genome-wide association studies have linked thousands of SNPs to disease risk, but the vast majority of those hits fall in non-coding regions. Non-coding SNPs typically influence disease by tweaking how much protein a gene produces (turning the volume up or down) rather than changing the protein itself. A c-SNP, by contrast, changes the protein’s blueprint directly. That makes the biological mechanism easier to trace, which is why c-SNPs often lead to clearer, more actionable findings in genetic research.
In practice, both types matter. A non-coding SNP that doubles the expression of a cancer-promoting gene can be just as dangerous as a c-SNP that makes the gene’s protein hyperactive. But when researchers find a c-SNP associated with a disease, they can often pinpoint the exact protein defect involved, which opens a more direct path toward targeted treatments.